stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Revenue
Organon & Co.'s revenue for fiscal 2025 was $6.2B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $6.1B. Over the past ten years it has ranged from $6.2B (fiscal 2022) to $10.5B (fiscal 2017); the current reading is higher than 22% of that period. Organon & Co. ranks 16th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $6.2B | (2.92%) |
| FY2024 | $6.4B | 2.24% |
| FY2023 | $6.3B | 1.44% |
| FY2022 | $6.2B | (2.06%) |
| FY2021 | $6.3B | (3.49%) |
| FY2020 | $6.5B | (16.01%) |
| FY2019 | $7.8B | (20.46%) |
| FY2018 | $9.8B | (6.89%) |
| FY2017 | $10.5B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.6B | 1.03% |
| Jun 2026 | $1.6B | 6.71% |
| Mar 2026 | $1.5B | (3.12%) |
| Dec 2025 | $1.5B | (5.93%) |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.6B |
| SNY Sanofi compare | $59.1B |
| NVO Novo Nordisk A/S compare | $51.9B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| GSK GSK PLC Sponsored ADR compare | $44.9B |
| BIIB Biogen Inc. compare | $10.3B |
| GRFS Grifols, S.A. compare | $8.8B |
| OGN Organon & Co. | $6.1B |
| AMRN Amarin Corporation PLC compare | $176.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on OGN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement